ClinicalTrials.gov ID NCT07040943
Sponsor West China Hospital
Information provided by Xingchen Peng, West China Hospital (Responsible Party)
Last Update Posted 2025-07-01
Brief Summary
This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.
Detailed Description
Cancer is a leading global cause of death, with advanced cases posing significant treatment challenges due to low efficacy and severe side effects. Gene therapy, especially mRNA-based immunogene therapy, offers promise. IL-22 promotes tumor progression, and its antagonist, IL-22BP, can inhibit tumor growth.
Patients with refractory, metastatic solid tumors unresponsive to second-line therapy lack viable options. This study aims to establish a novel IL-22BP-based mRNA treatment for advanced cancers.